Promoter hypermethylation and protein expression of the p16 gene: Analysis of 43 cases of B-cell primary gastric lymphomas from China

Modern Pathology

Volumn 17, Issue 4, 2004, Pages 416-422

  Huang, Qin ^a   Ai, Lingbao ^b   Zhang, Zackery Y ^a   Fan, Chun Yang ^b   Weiss, Lawrence M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

p16 gene expression; Primary gastric lymphoma; Promotor hypermethylation

Indexed keywords

PROTEIN P16; DNA; PROTEIN P16INK4A;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; METASTASIS; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STOMACH LYMPHOMA; CHINA; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; STOMACH TUMOR; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CHINA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); STOMACH NEOPLASMS;

EID: 4644228483     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800072     Document Type: Article

References (37)

1. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42-55.
2. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-F177.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
4. Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
5. Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. In: Vogt PAJaPK (ed). DNA Methylation and Cancer, 1st edn. Springer-Verlag: New York, Berlin, Heidelberg, 2000, pp. 35-50.
6. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-212.
7. Heinzel PA, Balaram P, Bernard HU. Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer 1996;68:420-423.
8. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-895.
9. El-Naggar AK, Lai S, Clayman G, et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997;151:1767-1774.
10. Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19:299-304; (see comments).
11. Reznikoff CA, Yeager TR, Belair CD, et al. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 1996;56:2886-2890.
12. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-3424.
13. Bai M, Vlachonikolis J, Agnantis NJ, et al. Low expression of p27 protein combined with altered p53 and RB/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large cell lymphomas. Mod Pathol 2001;14:1105-1113.
14. Gronbaek K, de Nully Brown P, Moller MB, et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 2000;14:1727-1735.
15. Rosas SLB, Koch W, Carvalho MDC, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;61:939-942.
16. Zhang ZY, Weiss LW, Vardiman JW, et al. Histologic and immunophenotypic features of 46 cases of primary gastric lymphoma from China. Mod Pathol 2002;15: A1126 (abstract).
17. Isaacson PG, Muller-Hermelink HK, Piris MA, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Jaffe ES, Harris NL, Stein H (eds). Pathology and Genetics: Tumor of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumors. IARC Press: Lyon, 2001, pp. 157-160.
18. Ai L, Stephenson KK, Ling W, et al. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol 2003;16:944-950.
19. Liu K, Zuo C, Luo QK, et al. Promoter hypermethylation and inactivation of hMLH1, a DNA mismatch repair gene, in head and neck squamous cell carcinoma. Diagn Mol Pathol 2003;12:50-56.
20. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104.
21. Liu H, Ye H, Dogan A, et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001;98:1182-1187.
22. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002;99:3-9.
23. Du MQ, Peng H, Liu H, et al. BCL10 gene mutation in lymphoma. Blood 2000;95:3885-3890.
24. Sanchez-Beato M, Saez AI, Navas IC, et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 2001;159:205-213.
25. Dalle JH, Fournier M, Nelken B, et al. P16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood 2001;99:2620-2623.
26. Child FJ, Scarisbrick JJ, Calnje E, et al. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. J Invest Dermatol 2002;118:941-948.
27. Han S, Ahn SH, Park K, et al. P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res Treat 2001;70:205-212.
28. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997;74:535-537.
29. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6:1845-1853.
30. Newcomb EW, Cohen H, Lee SR, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 1998;8:55-67.
31. Miettinen H, Kononen J, Sallinen P, et al. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neuro-Oncol 1999;41:205-211.
32. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16INK4a expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-2819.
33. Kwong J, Lo KW, To KF, et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 2002;8:131-137.
34. Navas IC, Algara P, Mateo M, et al. p16 (INK4a) is selectively silenced in the tumoral progression of mycosis fungoides. Lab Invest 2002;82:123-132.
35. Kim YS, Kim JS, Jung HC, et al. Regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: possible association with p16 hypermethylation. J Gastroent 2002;37:17-22.
36. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas (review). Blood 2003;101:1220-1235.
37. Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999;96:35-45.